Stock 0LTI WATERS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Waters Corporation London S.E.

Equities

0LTI

US9418481035

Advanced Medical Equipment & Technology

Delayed London S.E.
Other stock markets
 10:25:40 2024-06-06 am EDT 		5-day change 1st Jan Change
304.8 USD -2.20% Intraday chart for Waters Corporation -1.99% -7.18%
Jun. 05 Transcript : Waters Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 09:30 AM
May. 29 Waters Insider Bought Shares Worth $332,900, According to a Recent SEC Filing MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 15,055 15,352 22,742 20,352 19,466 17,829 - -
Enterprise Value (EV) 1 16,399 16,265 23,687 21,445 21,426 19,174 18,903 18,816
P/E ratio 26.9 x 29.6 x 33.4 x 29.2 x 30.4 x 27.8 x 24.5 x 22.1 x
Yield - - - - - - - -
Capitalization / Revenue 6.26 x 6.49 x 8.16 x 6.85 x 6.58 x 6.01 x 5.67 x 5.37 x
EV / Revenue 6.81 x 6.88 x 8.5 x 7.22 x 7.25 x 6.47 x 6.01 x 5.67 x
EV / EBITDA 19.8 x 19.7 x 24.5 x 20.9 x 19.9 x 17.8 x 16.5 x 15.2 x
EV / FCF 34.2 x 26.3 x 40.4 x 49.2 x 48.5 x 25.6 x 23 x 23.6 x
FCF Yield 2.92% 3.8% 2.47% 2.03% 2.06% 3.91% 4.35% 4.24%
Price to Book -73.6 x 66.4 x 61.6 x 41 x 17 x 9.67 x 7.23 x 5.68 x
Nbr of stocks (in thousands) 64,434 62,048 61,036 59,408 59,127 59,320 - -
Reference price 2 233.6 247.4 372.6 342.6 329.2 300.6 300.6 300.6
Announcement Date 2/4/20 2/2/21 2/1/22 2/15/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,407 2,365 2,786 2,972 2,956 2,965 3,146 3,319
EBITDA 1 829.9 824.2 965.9 1,029 1,079 1,077 1,149 1,235
EBIT 1 734.3 699.4 841.4 898.1 912.9 920.6 991.9 1,060
Operating Margin 30.51% 29.57% 30.2% 30.22% 30.88% 31.05% 31.52% 31.93%
Earnings before Tax (EBT) 1 678.2 610.9 806.2 837.8 736.2 731.8 806.4 871.1
Net income 1 592.2 521.6 692.8 707.8 642.2 647.1 717.6 756.4
Net margin 24.61% 22.05% 24.87% 23.81% 21.72% 21.83% 22.81% 22.79%
EPS 2 8.690 8.360 11.17 11.73 10.84 10.80 12.29 13.59
Free Cash Flow 1 479.3 618.1 586 435.7 442.2 749.2 821.6 797.6
FCF margin 19.91% 26.13% 21.03% 14.66% 14.96% 25.27% 26.11% 24.03%
FCF Conversion (EBITDA) 57.75% 75% 60.67% 42.37% 40.99% 69.54% 71.53% 64.58%
FCF Conversion (Net income) 80.93% 118.51% 84.58% 61.57% 68.85% 115.77% 114.49% 105.45%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/4/20 2/2/21 2/1/22 2/15/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 836.4 690.6 714.3 708.6 858.5 684.7 740.6 711.7 819.5 636.8 699.7 736.9 887.5 685.6 749.6
EBITDA 1 304.8 242 237.3 228.8 320.5 214.7 258 272.3 333.8 220.4 244.2 272.5 355.5 224.3 270.3
EBIT 1 272.8 209.3 203.1 196.6 289.2 183.6 219.1 224.5 285.7 171.9 203.8 229.3 315.4 192.2 228.7
Operating Margin 32.61% 30.31% 28.43% 27.74% 33.68% 26.81% 29.59% 31.54% 34.86% 26.99% 29.13% 31.12% 35.53% 28.04% 30.51%
Earnings before Tax (EBT) - - - 183.4 275.5 165.2 180.3 153.2 237.6 - - - - - -
Net income 1 216.2 159.8 164.9 156 227.1 140.9 150.6 134.6 216.2 102.2 148 162.2 253 - -
Net margin 25.85% 23.14% 23.08% 22.02% 26.45% 20.58% 20.33% 18.91% 26.38% 16.05% 21.15% 22.01% 28.51% - -
EPS 2 3.520 2.620 2.720 2.600 3.810 2.380 2.550 2.270 3.650 1.720 2.317 2.663 4.053 2.250 2.770
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/1/22 5/3/22 8/2/22 11/1/22 2/15/23 5/9/23 8/2/23 11/7/23 2/6/24 5/7/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,344 913 945 1,093 1,960 1,345 1,075 987
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.619 x 1.108 x 0.9779 x 1.063 x 1.816 x 1.249 x 0.9356 x 0.7991 x
Free Cash Flow 1 479 618 586 436 442 749 822 798
ROE (net income / shareholders' equity) 87.7% 243% 232% 166% 84.2% 44.5% 34.3% 28.5%
ROA (Net income/ Total Assets) 18.9% 21.1% 23.4% 22.7% 17.6% 14.3% 14.3% 14%
Assets 1 3,142 2,473 2,960 3,112 3,646 4,541 5,033 5,387
Book Value Per Share 2 -3.170 3.730 6.050 8.360 19.40 31.10 41.60 52.90
Cash Flow per Share 2 9.430 12.70 12.00 10.10 10.20 12.30 13.40 16.40
Capex 1 164 172 161 176 161 158 166 173
Capex / Sales 6.81% 7.29% 5.79% 5.92% 5.43% 5.31% 5.29% 5.2%
Announcement Date 2/4/20 2/2/21 2/1/22 2/15/23 2/6/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Waters Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
300.6 USD
Average target price
325.4 USD
Spread / Average Target
+8.26%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+9.24% 221B
DANAHER CORPORATION Stock Danaher Corporation
+15.84% 198B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+23.95% 148B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+31.67% 112B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+4.37% 66.85B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+14.99% 52.84B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+4.85% 50.86B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-4.47% 38.75B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
-0.41% 35.15B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. WAT Stock
  4. 0LTI Stock
  5. Financials Waters Corporation